Xeris Biopharma Holdings Inc
NASDAQ:XERS

Watchlist Manager
Xeris Biopharma Holdings Inc Logo
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Watchlist
Price: 3.09 USD 1.64% Market Closed
Market Cap: 460.4m USD
Have any thoughts about
Xeris Biopharma Holdings Inc?
Write Note

Wall Street
Price Targets

XERS Price Targets Summary
Xeris Biopharma Holdings Inc

Wall Street analysts forecast XERS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XERS is 4.86 USD with a low forecast of 3.03 USD and a high forecast of 6.93 USD.

Lowest
Price Target
3.03 USD
2% Downside
Average
Price Target
4.86 USD
57% Upside
Highest
Price Target
6.93 USD
124% Upside

XERS Last Price Targets
Xeris Biopharma Holdings Inc

The latest public price target was made on Nov 11, 2024 by Oren Livnat from H.C. Wainwright , who expects XERS stock to rise by 114% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Oren Livnat
H.C. Wainwright
6.6 USD
Upside 114%
1 week ago
Nov 11, 2024
Xeris Pharmaceuticals (XERS) PT Raised to $6.60 at H.C. Wainwright
StreetInsider
Leland Gershell
Oppenheimer
5 USD
Upside 62%
1 month ago
Oct 23, 2024
Oppenheimer Reiterates Outperform Rating on Xeris Pharmaceuticals (XERS)
StreetInsider
David Amsellem
Piper Sandler
3 USD
Downside 3%
6 months ago
May 10, 2024
Xeris Pharmaceuticals (XERS) PT Lowered to $3 at Piper Sandler
StreetInsider
Oren Livnat
H.C. Wainwright
Price Target 6.6 USD
Upside/Downside 114%
View Source
Leland Gershell
Oppenheimer
Price Target 5 USD
Upside/Downside 62%
View Source
David Amsellem
Piper Sandler
Price Target 3 USD
Upside/Downside 3%
View Source
Xeris Biopharma Holdings Inc Competitors:
Price Targets
CAMX
Camurus AB
25% Upside
SDZ
Sandoz Group AG
4% Upside
000513
Livzon Pharmaceutical Group Inc
9% Upside
605507
Guobang Pharma Ltd
15% Upside
688185
CanSino Biologics Inc
1% Upside
3692
Hansoh Pharmaceutical Group Company Ltd
29% Upside
KILITCH
Kilitch Drugs (India) Ltd
53% Upside
4577
Daito Pharmaceutical Co Ltd
32% Upside

Revenue
Forecast

Revenue Estimate
Xeris Biopharma Holdings Inc

For the last 6 years the compound annual growth rate for Xeris Biopharma Holdings Inc's revenue is 116%. The projected CAGR for the next 3 years is 19%.

116%
Past Growth
19%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Xeris Biopharma Holdings Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Xeris Biopharma Holdings Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-55%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XERS's stock price target?
Price Target
4.86 USD

According to Wall Street analysts, the average 1-year price target for XERS is 4.86 USD with a low forecast of 3.03 USD and a high forecast of 6.93 USD.

What is Xeris Biopharma Holdings Inc's Revenue forecast?
Projected CAGR
19%

For the last 6 years the compound annual growth rate for Xeris Biopharma Holdings Inc's revenue is 116%. The projected CAGR for the next 3 years is 19%.

Back to Top